On April 25, 2025, Tonix Pharmaceuticals disclosed its preliminary quarterly results for Q1 2025, reporting $131.7 million in cash, a net loss of approximately $16.8 million, and a reduction in operating cash use compared to the previous year, while also noting the discontinuation of its Phase 2 CATALYST study due to slow enrollment.